On September 3-5, 2009, the 3rd Intercontinental Cooperative ITP Study Group (ICIS) Expert Meeting was held in Basel, Switzerland. After Bürgenstock (2003) and Yverdon (2006) , the meeting is gaining a status of tradition. More than 100 experts involved in basic science and clinical research met to discuss consensus issues and development of strategies in immune thrombocytopenia (ITP). This issue of Annals of Hematology represents a compilation of lectures and working group discussions. The four working groups "Basic science", "Management endpoints of ITP", "Chronic ITP", and "Future research: resources and regulations" were preceded by lectures of the same topic. Speakers were invited to send a review article of their lecture. The articles of Clemetson and Panzer, Tamary et al., Grainger et al., and Zehnder et al. represent summaries of the working group discussions, which were submitted after the meeting and after consensus work of co-authors and participants.
The ICIS Expert Meeting was a great opportunity to exchange new knowledge and to plan for the future. Immune thrombocytopenia, formerly called idiopathic or immune thrombocytopenic purpura is a bleeding diathesis with the hallmark of thrombocytopenia, resulting from premature platelet destruction by the monocytic-phagocytic system and by certain degree of platelet production failure. In a majority of patients, autoantibodies of various specificities can be detected, however, not in every patient, which indicates heterogeneity of the etiology and immune pathophysiology in patients with ITP. It is this heterogeneity which may be responsible for different degrees of responses to therapeutic interventions, and also for the many debates and controversies around ITP. The terminology, definitions, and the practice guidelines characterizing ITP have recently been improved by the international harmonization report [1] and by the international consensus report [2] . Within the 12-year experience of ICIS registries, we learned how to formulate registry questions, electronic data management including online processes, and data quality assessments. Data control and evaluation need cautiousness and high professional experience. Scientific results and publications have to be peer-reviewed by experts of registries. Ongoing communication and discussion through regular international meetings support this process.
Attending experts, speakers, and manuscript authors did a great job and made our meeting a fruitful and successful event. Our thanks go to all active participants of the meeting and to all ICIS investigators. Warm thanks go to Verena Stahel, Caroline Martin, and Monika Imbach, our ICIS office staff, as well as to Erika Scheibli, secretary, who are all wonderful organizers. The research activities of ICIS are supported by the ITP Foundation founded by family McGuire, the Eduard Waeffler-Ludwig Stiftung Basel Fund, and the University Children's Hospital Basel, as well as industrial support by Amgen, Biotest, CSL Behring, F. Hoffmann-La Roche, GlaxoSmithKline, and PPTA.
ITP reflects since its description by Paul Gottlieb Werlhof a fast-changing field. It becomes clearer that it is not a disorder, not Werlhof's disease, but rather an immunological phenomenon caused by different factors and mechanisms. We hope that such ICIS meetings stimulate the participants and all participating and interested investigators to maintain their enthusiasm and energy to further develop basic and clinical research which ultimately will help children and adults with ITP. All meeting participants and ICIS investigators can be seen by visiting our homepage www.itpbasel.ch.
